{"version":"1.0","provider_name":"Myanmar Newswire","provider_url":"https:\/\/myanmarnewswire.com","author_name":"admin","author_url":"https:\/\/myanmarnewswire.com\/author\/admin\/","title":"Taiho Pharmaceutical Obtains Approval to Manufacture and Market NK1 Receptor Antagonist Arokaris\u00ae I.V. Infusion 235mg in Japan - Myanmar Newswire","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"KSjCH6WJPg\"><a href=\"https:\/\/myanmarnewswire.com\/taiho-pharmaceutical-obtains-approval-to-manufacture-and-market-nk1-receptor-antagonist-arokaris-i-v-infusion-235mg-in-japan\/\">Taiho Pharmaceutical Obtains Approval to Manufacture and Market NK1 Receptor Antagonist Arokaris\u00ae I.V. Infusion 235mg in Japan<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/myanmarnewswire.com\/taiho-pharmaceutical-obtains-approval-to-manufacture-and-market-nk1-receptor-antagonist-arokaris-i-v-infusion-235mg-in-japan\/embed\/#?secret=KSjCH6WJPg\" width=\"600\" height=\"338\" title=\"&#8220;Taiho Pharmaceutical Obtains Approval to Manufacture and Market NK1 Receptor Antagonist Arokaris\u00ae I.V. Infusion 235mg in Japan&#8221; &#8212; Myanmar Newswire\" data-secret=\"KSjCH6WJPg\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n<\/script>\n","description":"Taiho Pharmaceutical Obtains Approval to Manufacture and Market NK1 Receptor Antagonist Arokaris\u00ae I.V. Infusion 235mg in Japan Tokyo, Japan, and Lugano, Switzerland March 28, 2022 \u2013 Taiho Pharmaceutical Co., Ltd. (hereinafter \u201cTaiho\u201d) and Helsinn Group (hereinafter \u201cHelsinn\u201d), announced today that Taiho has been granted approval from the Japanese Ministry of Health, Labour and Welfare to [\u2026]","thumbnail_url":"https:\/\/ci6.googleusercontent.com\/proxy\/FE21GZA4qQp7wwzkoVY5GFrPRFSgD0q1jB2IuObdA0JhmBTCCDR_AoczX-INj6rs3ANIwQBTaB0trAhDi-JnoXWXAxnSPfmWsrL0_og-IXk8izbPsZEapu2xOtPK0NQbQpGuib7lvTsZ=s0-d-e1-ft#https:\/\/ml-eu.globenewswire.com\/Resource\/Download\/a858b839-8bb8-45c6-be0a-11047d000dd4"}